← Back to directory
F
Forbion
Naarden, NetherlandsWebsite ↗
Forbion is a leading global venture capital firm with deep expertise in Europe, investing in innovative biotech companies across all stages of (bio-)pharmaceutical drug development. Additionally, the firm addresses planetary health challenges through its BioEconomy fund strategy, backing companies that develop sustainable solutions in food, agriculture, materials, and environmental technologies.
Last raised
Oct 2024
1y 10mo ago
Latest fund size
$1.3B
Forbion Growth Opportunities III
AUM
$5.5B
estimated
Funds raised
Capital this firm has raised, newest first
Forbion Growth Opportunities III
Oct 2024
$1.3B
Forbion Ventures VII
Oct 2024
$980M
Forbion BioEconomy Fund I
Jan 2024
$220M
Forbion Ventures Fund VI
Apr 2023
$825M
Forbion Growth Opportunities Fund II
Apr 2023 · FGOF II
$660M
Forbion Growth Opportunities Fund I
Apr 2021
$396M
Forbion V
Dec 2020 · Ventures Fund V
$506M
Forbion Growth Opportunities Fund
Jul 2020
$208M
Forbion IV
Oct 2018 · Ventures Fund IV
$420M
Forbion Capital Fund III
Jan 2016 · FCF III
$201.3M
Forbion Ventures Fund II
Jan 2010
$209M
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| RQ Bio | — | — | Jun 2026 | |
| Mestag Therapeutics | Series A | — | May 2026 | |
| Tropic BiosciencesLead | Series C | $105M | Mar 2026 | |
| Pheon Therapeutics | — | — | May 2024 |
Sources
Where this data came from